Overview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist
|
|
|
- Arline Harrison
- 5 years ago
- Views:
Transcription
1 Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist
2 No conflicts of interest
3 OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic criteria for cystic fibrosis Understand role of lung function testing in cystic fibrosis Know management strategies of a child with cystic fibrosis Review extrapulmonary manifestations of cystic fibrosis
4 INTRODUCTION Cystic Fibrosis is the most common, inherited, life shortening, condition in Caucasians 1 in 3000 live births; Carrier rate approx. 1 in 30 Autosomal recessive mutation in CFTR gene on chromosome 7 Nearly 2000 different mutations, most common is delf508 Defective sodium, chloride and bicarbonate ion transport
5 DIAGNOSIS AND PATHOGENESIS Newborn screening Sweat chloride, genetic testing Lungs appear morphologically normal at birth Increased inflammation and mucus plugging Kendig and Chernicks s text book Repeated infections and lung damage
6 PATHOGENESIS Segmental hyperinflation or atelectasis, postinflammatory blebs, bronchiectasis,pneumothorax Bronchial artery hypertrophy and hemoptysis Kendig and Chernicks s text book Bacteremia and sepsis are rare European respiratory society
7 BRONCHIECTASIS Kendig and Chernicks s text book
8 AIRWAY ORGANISMS Pediatr Clin North Am. doi: /j.pcl
9 PFT Normal PFT does not imply that there is no lung disease Changes can be subtle Lung volumes, body plethysmography, multiple breath washout CHEST , DOI: ( /chest
10 SCREENING Respiratory Spirometry at every visit (quarterly) Sputum culture CXR yearly Full PFT every year Non-respiratory CBC, liver function, PT/INR, PTT, fecal elastase Mental health screening Bone scan (DEXA)
11 MANAGEMENT Kendig and Chernicks s text book
12 PULMONARY EXACERBATION Increased cough Change in mucus- color, consistency, amount Drop in FEV1 Poor appetite, weight loss Fatigue Fever, increased inflammatory markers are NOT always seen
13 MANAGEMENT OF PULMONARY EXACERBATION Augmented airway clearance Antibiotics- at least 2 weeks Nutrition
14 HEMOPTYSIS IN CF Cause for concern Admit patient HOLD AIRWAY CLEARANCE AND MOST INHALED THERAPIES Quantify Antibiotics Vitamin K Bronchial artery embolization
15 OTHER ASPECTS OF CYSTIC FIBROSIS Upper airway: sinusitis, nasal polyps GI disease- meconium ileus, rectal prolapse Pancreatic insufficiency Liver disease CF related diabetes Science direct
16 NUTRITION Pancreatic insufficiency Poor appetite Increased energy expenditure Require pancreatic enzyme supplements High protein, high calorie diet Affects quality of life and outcome
17 AIRWAY CLEARANCE Started very early in newborn period (newborn screen) Done regularly To clear mucus plugs and relieve obstruction Prevent infection and inflammation Preserve lung function
18 AIRWAY CLEARANCE Albuterol Hypertonic Saline Deoxyribonuclease Inhaled corticosteroids Inhaled antibiotics
19 ALBUTEROL Airway clearance Bronchospasm Routine use- no strong evidence for or against Useful in patients with strong bronchodilator response
20 HYPERTONIC SALINE Ages 6 and up SHIP and other infant studies 3-7% NaCl Hydration of airway surface liquid Induces cough Can cause bronchospasm
21 DORNASE ALPHA/ PULMOZYME Well studied in CF bronchiectasis Dissolves DNA of neutrophils in sputum High net benefit, especially in moderate to severe lung disease
22 DORNASE ALPHA/ PULMOZYME FOR NON-CF BRONCHIECTASIS 349 adults with idiopathic bronchiectasis, stable disease received aerosolized dornase alfa or placebo twice daily for 24 weeks Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received the inhaled mucolytic agent compared with placebo O Donnell AE, et al. Chest 1998; 113:
23 INHALED ANTIBIOTICS Pseudomonas aeruginosa- frequency of exacerbations, decline in lung function Inhaled Tobramycin 300 mg BID Dry powder inhaler 112 mg BID Treatment for eradication for 28 days Suppression of chronic colonization for 28 days every other month
24 INHALED ANTIBIOTICS Inhaled Aztreonam/ Cayston 75mg BID Inhaled Colistin Inhaled Vancomycin powder for MRSA Inhaled Amikacin for NTM Inhaled nitric oxide currently under research
25 INHALED CORTICOSTEROIDS Asthma- airway hyperreactivity ABPA
26 ORDER OF TREATMENTS Albuterol Hypertonic saline Vest Pulmozyme Inhaled corticosteroids Inhaled antibiotics
27 ACT Manual CPT HFCWO Positive expiratory pressure (PEP) Oscillating PEP Intrapulmonary percussive ventilation Frequencer, Vibralung Other: Active cycle breathing technique (ACBT) Autogenic drainage Exercise
28 ACT Age Developmental/ skill level Patient preference Insurance Family s ability Routine versus exacerbation Travel Response to treatment
29 HFCWO Oscillatory air flow- break mucus away from walls and move then to central airways Central and peripheral airway clearance Physical nature of mucus also affected Hill-Rom Vest fit, frequency, pressure InCourage
30 MINNESOTA PROTOCOL Frequency Pressure Huff cough 8 10 Huff cough during pause 9 10 Huff cough during pause Huff cough during pause 18 6 Huff cough during pause 19 6 Huff cough during pause 20 6 Huff cough during pause *If the pressure of 10 is uncomfortable, use the Starting Pressure setting
31 PERCUSSION/ VIBRATION Disks or pods which percuss and vibrate Afflo vest and Monarch vest Monarch Afflovest
32 INTRAPULMONARY PERCUSSIVE VENTILATION Internal percussion Via mask, mouth piece, tracheostomy or ET tube Loosens mucus IPV, Metaneb, CoughAssist E70
33 PEP Breathing against pressure stents airways open Air into distal airways via collateral channels and gets behind secretions Therapep, bubble, Respionics PEP
34 Oscillating PEP PEP with oscillations on exhalation AerobikA Flutter Acapella
35 ACT Postural drainage- head down positions no longer recommended Huffing: mobilize and clear secretions Gentle coughing Different levels of vital capacity Autogenic drainage Tidal breathing at different levels of TLC 3 second breath hold Expiratory airflow mobilizes secretions
36 EQUIPMENT CFF
37 CLEANING Cleaning: Warm soapy water, dishwashing soap Rinse: with tap water ok for initial rinse, but use only sterile water for final rinse after disinfecting Disinfect: Boil, microwave, dishwasher, soak in hydrogen peroxide, isopropyl alcohol Air dry overnight
38 HOSPITAL Disposable: Rinse with water after each use. Replace after 24 hours Non-disposable: Clean, disinfect, air-dry
39 INFECTIOUS CONTROL Gown, mask, gloves Order of patient depends on patient s airway organism Amazon Hand washing PFT done in negative pressure room HEPA filter or 30 minute gap in-between filters
40 INFECTIOUS CONTROL Private room Can leave room with gown and mask 6 feet between any 2 CF patients Use dedicated disposable equipment Rules exempted for family members
41 INFECTIOUS CONTROL Hand hygiene The most effective means of preventing person-to-person transmission of bacteria is good hand hygiene. Patients must clean their hands with alcohol-based handwash or soap before leaving their rooms and before entering and leaving any common rooms. Hand cleaning should be performed after coughing spells Masks All patients with cystic fibrosis are required to wear a mask when outside of their own rooms Masks should cover both nose and mouth Masks should be changed at least every 30 minutes or when moist or soiled
42 SUMMARY CF is a complex condition that affects various organ systems Pulmonary disease is major cause of morbidity and mortality Appropriate airway clearance is important in maintaining lung functinon One size does not fit all Best technique is one that the patient will use
43 REFERENCES 1. Kendig and Chernick s Disorders of the respiratory tract in children 1. G Steinkamp, et.al., On Behalf Of The German CFQA Group. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) 1. Cff.org 1. O'Donnell AE1 et.al.treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhdnase Study Group.Chest.1998 May;113(5): CFF Respiratory: Which nebulizer for which drug? 1. Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease; 2017, Pages Pediatr Clin North Am Aug;63(4): Cystic Fibrosis: Microbiology and Host Response. Zemanick ET1, Hoffman LR2.
44 QUESTIONS?
Respiratory Care Services Basic Care of the CF Inpatient
Respiratory Care Services Basic Care of the CF Inpatient Overview : The Respiratory Therapist should explain all the equipment used to the patient in the hospital, for discharge and why it is important
What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
Disclaimer. Objectives. I can t cough it up! Airway Clearance Therapy. Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist
I can t cough it up! Airway Clearance Therapy Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist 1 Disclaimer Name of presenter: Heather Murgatroyd, BA, RRT, RPSGT Name of employer: RespirTech I
Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis
Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem
National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
Corporate Medical Policy
Corporate Medical Policy Oscillatory Devices for the Treatment of Respiratory Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: oscillatory_devices_for_treatment_of_respiratory_conditions
Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance
acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance Investigating Questions Each acapella vibratory PEP therapy system uniquely provides PEP therapy by
CYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT
PURPOSE Physiotherapy role for inpatients with cystic fibrosis. POLICY STATEMENTS On admission to hospital all patients will be assessed by the physiotherapist within 24 hours. Physiotherapists have standing
The objectives of this presentation are to
1 The objectives of this presentation are to 1. Review the mechanics of airway clearance 2. Understand the difference between secretion mobilization and secretion clearance 3. Identify conditions that
Cystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
A Place For Airway Clearance Therapy In Today s Healthcare Environment
A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will
UNDERSTANDING CYSTIC FIBROSIS
UNDERSTANDING CYSTIC FIBROSIS INTRODUCTION Cystic fibrosis is a chronic disease that affects the respiratory and gastrointestinal systems. People with cystic fibrosis have a genetic defect of the lungs
Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
Navigating the Hills & Valleys of CF Lung Disease: Keeping Lungs Healthy
This Web cast has 2 parts: Part 1 Keeping Lungs Healthy Part 2 Treating Disease Navigating the Hills & Valleys of CF Lung Disease: Keeping Lungs Healthy This Web cast is supported by an unrestricted educational
4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
Carole Wegner RN, MSN And Lori Leiser CRT
Airway Clearance Carole Wegner RN, MSN And Lori Leiser CRT Topics Suctioning and suctioning equipment Medications to facilitate t airway clearance Bronchial hygiene modalities Preparing for suctioning
CF: Information for Case Managers. Cindy Capen MSN, RN Pediatric Pulmonary Division University of Florida
CF: Information for Case Managers Cindy Capen MSN, RN capencl@peds.ufl.edu Pediatric Pulmonary Division University of Florida About your speaker 25+ years in pulmonary Coordinator for CF Center and CF
Respiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
Cystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
Cystic Fibrosis. Information for Caregivers
Cystic Fibrosis Information for Caregivers Arkansas Children s Hospital is an accredited Cystic Fibrosis Care Center by the National Cystic Fibrosis Foundation Cystic Fibrosis: Information for Caregivers
FEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Description Oscillatory devices are alternatives to
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX Pioneer of Respiratory Medicine 2016 marked 200th anniversary of his
Evaluation of Patients with Diffuse Bronchiectasis
Evaluation of Patients with Diffuse Bronchiectasis Dr. Patricia Eshaghian, MD Assistant Clinical Professor of Medicine Director, UCLA Adult Cystic Fibrosis Affiliate Program UCLA Division of Pulmonary
FACTS ABOUT. Cystic Fibrosis. What Is Cystic Fibrosis. What Are the Signs and Symptoms of CF?
FACTS ABOUT Cystic Fibrosis What Is Cystic Fibrosis Cystic fibrosis (CF) is a chronic, progressive, and frequently fatal genetic (inherited) disease of the body s mucus glands. CF primarily affects the
Active Cycle of Breathing Technique
Active Cycle of Breathing Technique Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust wide): Review date (when
Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England E03X05/01 Information Reader Box (IRB) to be inserted on inside
Section: Durable Medical Equipment Last Reviewed Date: June Policy No: 45 Effective Date: September 1, 2014
Medical Policy Manual Topic: Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders Date of Origin: May 26, 2011 Section: Durable Medical Equipment Last Reviewed Date:
Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)
Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from
Levine Children s Hospital. at Carolinas Medical Center. Respiratory Care Department
Page 1 of 7 at Carolinas Medical Center 02.04 Pediatric Patient-Centered Respiratory Care Protocol Application of Chest Physical Therapy Created: 1/98 Reviewed: 4/03, 1/05, 6/08 Revised: Purpose: To describe
Physiotherapy treatment in cystic fibrosis: airway clearance techniques. Factsheet March Fighting for a
Physiotherapy treatment in cystic fibrosis: airway clearance techniques Factsheet March 2013 Fighting for a Life Unlimited Physiotherapy treatment in cystic fibrosis: airway clearance techniques Introduction
Skills Checklist Manual
Skills Checklist Manual Alexandra L. Quittner, Ph.D. Kristen K. Marciel, Ph.D. Ivette Cruz, M.S. University of Miami Quittner, Marciel, & Cruz, 2009 i revised 2/5/09 Table of Contents Instructions 1 Airway
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
of Cystic Fibrosis and Other Respiratory Disorders Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oscillatory Devices for the Treatment of Cystic Fibrosis
AFCH NEUROMUSCULAR DISORDERS (NMD) PROTOCOL
AFCH NEUROMUSCULAR DISORDERS (NMD) PROTOCOL A. Definition of Therapy: 1. Cough machine: 4 sets of 5 breaths with a goal of I:E pressures approximately the same of 30-40. Inhale time = 1 second, exhale
Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis
Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis APRIL 2018 Authors Steve Kent MD, CF Clinic Director, Victoria General Hospital (VGH), Victoria Mark Chilvers MD, CF Clinic Director, B.C.
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically
Cystic Fibrosis New Patient Binder Cystic Fibrosis Center Pediatric Pulmonary Division
An annotated table-of-contents for the Cystic Fibrosis New Patient Binder Pediatric Pulmonary Division Introduction This booklet is a summary of the key points in the detailed and comprehensive information
Protocol. Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other (10115) Medical Benefit Effective Date: 01/01/18 Next Review Date: 07/18 Preauthorization No Review Dates: 01/07, 03/08, 03/09, 03/10,
Navigating the Hills and Valleys of CF Lung Disease: Treating Disease
This Web cast has 2 parts: Part 1 Keeping Lungs Healthy Part 2 Treating Disease Navigating the Hills and Valleys of CF Lung Disease: Treating Disease This Web cast is supported by an unrestricted educational
Aerosol Therapy. Aerosol Therapy. RSPT 1410 Humidity & Aerosol Therapy Part 4
1 RSPT 1410 Humidity & Part 4 Wilkins Chapter 36; p. 801-806 2 Stability: the tendency for aerosol particles to remain in Size: the the particle, the greater the tendency toward stability the the particle,
The Respiratory System
130 20 The Respiratory System 1. Define important words in this chapter 2. Explain the structure and function of the respiratory system 3. Discuss changes in the respiratory system due to aging 4. Discuss
A review of Cystic Fibrosis
A review of Cystic Fibrosis Jennifer Landry md F.R.C.P.(C) Pulmonary & Critical Care Medicine McGill University Health Center Cystic Fibrosis One of the most common lethal inherited AR disorders in the
The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr.
The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr., PTRP Keywords: Active Cycle of Breathing Technique (ACBT), Pulmonary
Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England: 16029/P NHS England INFORMATION READER BOX Directorate Medical Operations and
Cleaning and Care Instructions
Cleaning and Care Instructions Westmed recommends that principles and practices related to cleaning and disinfection of nebulizers and related respiratory equipment, as published in the Infection Prevention
Effective Date: August 31, 2006 SUBJECT: CARE AND USE OF NEBULIZER AND INTERMITTENT POSITIVE PRESSURE BREATHING DEVICE
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Treatments POLICY NUMBER: 421 Effective Date: August 31, 2006 SUBJECT: CARE AND USE OF NEBULIZER AND INTERMITTENT POSITIVE PRESSURE
Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
Positive Expiratory pressure (PEP), Acapella and Flutter
Positive Expiratory pressure (PEP), Acapella and Flutter Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust
Cystic fibrosis: hitting the target
Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas
Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses
Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects
Cystic Fibrosis. Presented by: Chris Belanger & Dylan Medd
Cystic Fibrosis Presented by: Chris Belanger & Dylan Medd Outline What is Cystic Fibrosis? Signs, Symptoms & Diagnosis Who does it effect? General effects on daily life Managing Cystic Fibrosis Exercise
Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist
Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist Why Are People Affected Differently Neuromuscular Disease; A Spectrum Its severity varies widely within
High Frequency Chest Wall Oscillation Devices
High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: DME
1.40 Prevention of Nosocomial Pneumonia
1.40 Prevention of Nosocomial Pneumonia Purpose Audience Policy Statement: The guideline is designed to reduce the incidence of pneumonia and other acute lower respiratory tract infections. All UTMB healthcare
Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
Hypertonic Saline (7%) Administration Guideline (adults)
Hypertonic Saline (7%) Administration Guideline (adults) Full Title of Guideline: Author (include email and role): Hypertonic Saline (7%) Administration Guideline for Practice (Adults) Clair Martin, Senior
Introducing The Players!
PT and Cystic Fibrosis: A Successful Team from Birth to Healthy Aging! g Part I: Role of PT in the Disease of CF Introducing The Players! Anne Mejia Downs PT, MPH, CCS Rob Dekerlegand PT, MPT, CCS Anne
Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012
Mai ElMallah,MD Updates in Pediatric Pulmonary Care XII: An Interdisciplinary Program April 13, 2012 Recognize the importance of Pulmonary Function Testing in Cystic Fibrosis Be aware of different types
WELCOME 1/24/19. The Healthcare Environment Today. Airway Clearance Techniques. All Modes of Airway Clearance. Know which modality for which patient
WELCOME All Modes of Airway Clearance The Healthcare Environment Today Current Situation Respiratory complications are a major concern More focus on hospital acquired infections Changing Reimbursement
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines Inclusion Criteria: Age 1 year with cystic fibrosis admitted for a pulmonary exacerbation. Exclusion Criteria: ICU Admission Newborn with
Cystic fibrosis: From the gene to the disease
Cystic fibrosis: From the gene to the disease Christiane Knoop, MD, PhD Institut de Mucoviscidose de l ULB Hôpital Erasme christiane.knoop@erasme.ulb.ac.be Cystic fibrosis «The infant that tastes of salt
Alpha-1 Antitrypsin Deficiency Alpha-1 Lung Disease
Alpha-1 Antitrypsin Deficiency Alpha-1 Lung Disease Chronic obstructive pulmonary disease (COPD) affects millions of people each year. Chronic means long term, obstructive means it is hard to get air in
Appendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
Sputum, Gotta Love The Stuff!
Sputum, Gotta Love The Stuff! Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Georgia State University Objectives Differentiate mucus from
Chronic obstructive lung disease. Dr/Rehab F.Gwada
Chronic obstructive lung disease Dr/Rehab F.Gwada Obstructive lung diseases Problem is in the expiratory phase Lung disease Restrictive lung disease Restriction may be with, or within the chest wall Problem
Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en
Terapias no farmacológicas de aclaramiento de la vía aérea y soporte respiratorio muscular en el paciente ventilado: Estado del arte João Carlos Winck, MD, PhD Coordinator of the Respiratory Medicine Unit
Small Volume Nebulizer Treatment (Hand-Held)
Small Volume Aerosol Treatment Page 1 of 6 Purpose Policy Physician's Order Small Volume Nebulizer Treatment To standardize the delivery of inhalation aerosol drug therapy via small volume (hand-held)
Chronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
MASTER SYLLABUS
MASTER SYLLABUS 2018-2019 A. Academic Division: Health Science B. Discipline: Respiratory Care C. Course Number and Title: RESP 2490 Practicum IV D. Course Coordinator: Tricia Winters, BBA, RRT, RCP Assistant
RESPIRATORY REHABILITATION
RESPIRATORY REHABILITATION By: Dr. Fatima Makee AL-Hakak University of kerbala College of nursing CHEST PHYSIOTHERAPY Chest physiotherapy (CPT) includes: 1.Postural drainage. 2.Chest percussion and vibration.
Oxygen Therapy. 7. Partial Initiation of therapy
Oxygen Therapy 1. Nasal Initiation of therapy Cannula 2. Alteration of therapy 3. Change of equipment 4. Simple Mask Initiation of therapy 5. Alteration of therapy 6. Change of equipment 7. Partial Initiation
Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
Respiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
Signs and Symptoms of Chest Infections
Signs and Symptoms of Chest Infections Chest infection If you have been diagnosed with a lung condition you can be at greater risk of contracting a chest infection. Chest infections can be caused by a
High Frequency Chest Wall Oscillation Devices
High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 10/24/2014 Section: DME
Lecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
Contents. In this lecture, we will discuss: Tuberculosis. Asthma. Cystic fibrosis. Bronchopulmonary dysplasia. Miss.kamlah
1 Contents In this lecture, we will discuss: Tuberculosis. Asthma. Cystic fibrosis. Bronchopulmonary dysplasia. 2 Tuberculosis (TB) is caused by organism Mycobacterium tuberculosis, which is transmitted
TIP NO AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO PURPOSE.
AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO. 56-088-0618 PURPOSE. Healthcare workers risk exposure to exhaled aerosolized drugs along with infectious airborne pathogens during administration and routine
Cystic Fibrosis Panel Applications (Dornase Alfa) Contents
Cystic Fibrosis Panel Applications (Dornase Alfa) Contents Page 2-4: Entry and Stopping Criteria for Treatment with Dornase Alfa Page 5-9: Application and consent forms for a one month trail and long term
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
Medical Policy Manual Durable Medical Equipment, Policy No. 45 Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Next Review: June 2019 Last Review: June 2018 Effective:
IPV INTRAPULMONARY PERCUSSIVE VENTILATION IPV 23/03/2013 IPV INTRAPULMONARY PERCUSSIVE VENTILATION
INTRAPULMONARY PERCUSSIVE VENTILATION INTRAPULMONARY PERCUSSIVE VENTILATION FT Vilma Donizetti Valduce Hospital FT Vilma Donizetti Rehabilitation Center Villa Beretta Costa Masnaga, Lecco (I) It s a ventilatory
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress
Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
CYSTIC FIBROSIS Risk Factors Epidemiology Pathogenesis Defective protein synthesis (10%) Abnormal protein folding, processing & trafficking
CYSTIC FIBROSIS Risk Factors Caucasian Family history of CF Infection Exposure to allergens and tobacco Epidemiology Carrier frequency of 1 in 25 for Caucasians The most common lethal genetic disease affecting
I Need to Cough Ways to Keep Your Airways Clear
I Need to Cough Ways to Keep Your Airways Clear 2018 Annual Cure SMA Conference Richard Kravitz, MD Duke University School of Medicine Duke University Medical Center Durham, North Carolina Presenters Jane
Where Therapy is Moving Monarch Airway Clearance System
Where Therapy is Moving Monarch Airway Clearance System Mobile therapy that works. 1,2,3 The Monarch Airway Clearance System is a high frequency chest wall oscillation (HFCWO) therapeutic device with revolutionary
Non Cystic Fibrosis Bronchiectasis: How to Proceed?
Non Cystic Fibrosis Bronchiectasis: How to Proceed? Dr Ankit Parakh MD, DNB, MNAMS, RCPCH Fellow (UK), European Diplomate of Pediatric Respiratory Medicine ERS Fellowship Pediatric Medicine & NIV (GOSH,
NON-CYSTIC FIBROSIS BRONCHIECTASIS
NON-CYSTIC FIBROSIS BRONCHIECTASIS MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the
Bronchial Hygiene Therapy
WHITE PAPER Bronchial Hygiene Therapy OBJECTIVES At the conclusion of this paper the reader should have an understanding of the following: A background of chest physiotherapy, and rational for use of Positive
Rhianna Cenci, Sodexo Dietetic Intern
Rhianna Cenci, Sodexo Dietetic Intern Objectives Overview of CF and Treatments CF Medical Nutrition Therapy CF Case Study Cystic Fibrosis (CF) Overview Inherited chronic disease Produces unusually thick
TOWN OF FAIRFIELD HEALTH DEPARTMENT PUBLIC HEALTH NURSING
TOWN OF FAIRFIELD HEALTH DEPARTMENT PUBLIC HEALTH NURSING PROGRAM: School Health APPROVED BY: Board of Health POLICY: Nebulizer Therapy DATE: 5-10-93 PROCEDURE: a) Nebulizer Therapy With Non-oxygenated
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Policy Number: 1.01.15 Last Review: 3/2018 Origination: 3/2001 Next Review: 3/2019 Policy Blue Cross and Blue Shield
Positive Pressure Therapy
Positive Pressure Therapy Positive Pressure Therapy...2 What is Sleep Apnea?....2 Positive Pressure Machines..................................................... 4 Types..................................................................................